Typical and Atypical Antipsychotics – The Misleading Dichotomy

  title={Typical and Atypical Antipsychotics – The Misleading Dichotomy},
  author={David Fischer-Barnicol and Stefan Lanquillon and Ekkehard Haen and Peter Z{\"o}fel and Horst Josef Koch and Matthias Dose and Helmfried E. Klein},
  pages={80 - 87}
Objectives: (1) To investigate the risk of extrapyramidal motor side effects (EPS) associated with the prescription of different antipsychotics under naturalistic treatment conditions; (2) to test the rationale of the terms ‘typical’ and ‘atypical’ based on EPS rates. Design: Cross-sectional study in the federal state of Bavaria. Setting: 20 psychiatric hospitals in Bavaria. Participants: 6,061 inpatients, aged 18–65 years, with psychotic disorders. Main Outcome Measures: Co-medication with the… 

Figures and Tables from this paper

Antipsychotic treatment of schizophrenia: an update.
Meet the relatives: a reintroduction to the clinical pharmacology of ‘typical’ antipsychotics (Part 1)
A number of pragmatic trials have cast doubt on the concept of ‘atypicality’ in relation to anti-psychotic drugs, and some commentators have argued that the dichotomy between ‘typical’
Atypical Antipsychotic Drugs in the Treatment of Parkinson’s Disease
  • J. Friedman
  • Psychology, Medicine
    Journal of pharmacy practice
  • 2011
Double blind, placebo controlled trials (DBPCT) have shown that clozapine is effective at controlling the psychotic symptoms at doses far below those used in schizophrenia, without worsening motor function, even improving tremor, while DBPCT have demonstrated that olanzapine worsens motor function without improving psychosis.
Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
The incidence and severity of extrapyramidal syndrome differ amongst these antipsychotics, but the fact is that these drugs have not lived up to the expectation regarding their tolerability.
Atypical antipsychotics for psychosis in adolescents.
This systematic review collates and critiques evidence obtained on the use of various atypical antipsychotic medications for adolescents with psychosis, finding no data on service utilisation, economic outcomes, behaviour or cognitive response.
Some novelties and recommendations by swithing antipsychotics
The basic rules and ways of replacing antipsychotic drugs in different clinical situations are specified, and alerts, recommendations and suggestions when changing antipsychotics are summarized.
Schizophrenia: 1979-2009
The overall health of patients with schizophrenia is poor and mortality rates are excessive, and recovery (defined variously, but with a focus on counteracting disability and enhancing self-determination in the face of stigma) has become the main aim of treatment.
Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
It is concluded that the available literature examining the inter-section of antipsychotics, cognition, and metabolic effects in schizophrenia is sparse, but a relationship between metabolic comorbidity and worse cognitive function in patients with schizophrenia is suggested.


Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis
There is no clear evidence that atypical antipsychotics are more effective or are better tolerated than conventional antipsychotic drugs.
The Prevalence of Acute Extrapyramidal Signs and Symptoms in Patients Treated With Clozapine, Risperidone, and Conventional Antipsychotics
Risperidone is superior to conventional neuroleptics in that it causes fewer EPS levels that are intermediate between clozapine and conventional antipsychotic drugs.
Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia.
It is suggested that the association between EPS and TD may be limited to specific subtypes of TD, and peripheral TD showed a higher association with parkinsonism and with akathisia, suggesting that these symptoms may share a common pathophysiology.
Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality.
  • W. Glazer
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2000
The mechanisms of neuroleptic-induced EPS and tardive dyskinesia are reviewed and the relationship between these movement disorders and atypical antipsychotic agents is discussed.
Extrapyramidal side effects are unacceptable
  • J. Kane
  • Psychology, Medicine
    European Neuropsychopharmacology
  • 2001
Risperidone versus typical antipsychotic medication for schizophrenia.
Risperidone appears to have little or no additional effect on the positive and negative symptoms of schizophrenia but did have less tendency to cause movement disorders, largely in comparison with haloperidol.
Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.
Of the 58 patients exposed only to NT dosages of haloperidol, 72% clinically recovered within the 5-week trial, and higher dosages given to 47 patients did not lead to greater improvement in measures of psychosis, but did produce slightly greater declines in measuresof hostility.